<p>/PRNewswire/ - 德沃尼健康集團公司（&#34; <strong>Devonian</strong>&#34; 或 &#34; <strong>公司</strong>&#34;）（TSXV: GSD）（OTCQB: DVHGF）是一家專注於開發獨特解決方案以應對纖維炎症疾病的臨牀階段公司，欣然宣佈已任命丹尼斯·圖爾平（Dennis Turpin）為公司首席財務官，任命即日生效。圖爾平先生目前擔任公司董事會成員，並將繼續留任。在擔任首席財務官之前，他還曾擔任審計委員會主席，該職位將由皮埃爾·拉貝（Pierre Labbé）接任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg"/></p>
<p>圖爾平先生是一位經驗豐富的職業高管和註冊專業會計師（CPA），在財務、資本市場交易、業務發展以及併購方面擁有超過 25 年的豐富經驗，其中大部分時間在生物製藥行業工作。</p>
<p><em>&#34;我很高興歡迎丹尼斯，並相信他將幫助加強我們的管理方法，豐富我們的視角，提升我們的集體專業知識，並指導德沃尼的發展。&#34;首席執行官安德烈·P·布萊特（André P. Boulet）博士表示。</em></p>
<p>圖爾平先生將接替維克托里亞·克拉斯特瓦（Viktoria Krasteva），後者將繼續留在公司，協助確保在 2026 年 2 月 27 日之前的順利過渡。董事會感謝克拉斯特瓦女士對公司的貢獻，並祝願她在未來的事業中一切順利。</p>
<p>共向圖爾平先生授予 25,000 股股票期權。這些期權立即生效，行使價格為 11.50 美元，行使期限為授予日期後的 10 年。</p>
<p><strong>期權授予更新</strong></p>
<p>公司還希望更正於 2025 年 12 月 19 日發佈的新聞稿，關於向公司董事和顧問授予 2,948,056 股股票期權，以及向員工授予 385,950 股股票期權和向一名研發顧問授予 100,000 股股票期權。根據股票期權計劃的條款，股票期權的行使價格不得低於授予日期前一個交易日收盤時普通股的市場價格。因此，之前披露的行使價格 0.18 美元已更正為 0.19 美元，這是授予日期前一個交易日收盤時的適用市場價格。所有其他股票期權授予的條款保持不變。根據公司於 2026 年 1 月 22 日完成的股份合併，每 60 股合併前普通股對應 1 股合併後普通股，上述股票期權已根據公司股票期權計劃的條款自動調整。因此，每 60 股合併前期權現在代表 1 股合併後期權，修正後的行使價格 0.19 美元已調整為合併後每股 11.40 美元。期權數量已向下取整至下一個最小整數，以便持有人在行使時僅能購買整股普通股。</p>
<p><strong>關於德沃尼</strong></p>
<p>德沃尼健康集團公司是一家臨牀階段製藥公司，專注於開發針對各種自身免疫性纖維炎症疾病的藥物，採用新穎的治療方法以滿足未滿足的醫療需求。德沃尼的核心戰略是開發用於治療纖維炎症自身免疫疾病的處方藥，包括但不限於特應性皮炎、放射性皮炎和潰瘍性結腸炎。</p>
<p>德沃尼還參與開發高價值的藥妝產品，利用與其製藥產品相同的專有方法。德沃尼還擁有一家商業化子公司 Altius Healthcare LP，專注於在加拿大銷售處方藥，獲得品牌製藥公司的許可。</p>
<p>德沃尼健康集團公司成立於 2015 年，總部位於加拿大魁北克，擁有一座先進的提取設施。德沃尼在多倫多證券交易所創業板（&#34; <strong>交易所</strong>&#34;）（ <strong>TSXV: GSD</strong>）上市，並目前在 OTCQB 創業市場（ <strong>OTCQB: DVHGF</strong>）報價。</p>
<p>欲瞭解更多信息，請訪問 www.groupedevonian.com。</p>
<p><strong>關於前瞻性聲明的警示説明</strong> 本新聞稿中包含的所有聲明，除了歷史事實聲明外，包括上述&#34;關於德沃尼&#34;段落，均構成某些證券法意義上的&#34;前瞻性信息&#34;或&#34;前瞻性聲明&#34;（統稱為&#34;前瞻性聲明&#34;），並基於本新聞稿發佈時的預期、估計和預測。這些前瞻性聲明可能通過使用諸如&#34;打算&#34;、&#34;相信&#34;、&#34;期望&#34;或這些詞和短語的變體（包括否定和語法變體）來識別，或表明某些行動、事件或結果&#34;可能&#34;、&#34;可以&#34;、&#34;將&#34;或&#34;會&#34;被採取、發生或實現。</p>
<p>前瞻性聲明必然基於許多估計和假設，儘管公司在作出這些聲明時認為這些估計和假設是合理的，但本質上仍然受到重大商業、經濟和競爭不確定性及偶發事件的影響。這些估計和假設可能被證明是錯誤的。許多不確定性和偶發事件可能直接或間接影響實際結果，並可能導致實際結果與任何前瞻性聲明中所表達或暗示的結果存在重大差異。不能保證這些假設會被證明是正確的，也不能保證前瞻性聲明會被證明是準確的，因為實際結果和未來事件可能與這些聲明中預期的結果存在重大差異。</p>
<p>由於其本質，前瞻性聲明涉及固有的風險和不確定性，包括一般性和特定性風險，存在估計、預測、展望和其他前瞻性聲明未能實現或假設未能反映未來經驗的風險。前瞻性聲明的目的是提供有關管理層對未來的期望和計劃的信息。讀者應謹慎對待這些前瞻性聲明，不應過度依賴，因為許多重要的風險因素和未來事件可能導致實際結果與這些前瞻性聲明中表達的信念、計劃、目標、期望、預期、估計、假設和意圖存在重大差異。本新聞稿中所作的所有前瞻性聲明均受到這些警示性聲明以及我們在加拿大相關證券監管機構的其他文件中所作聲明的限制。公司不承擔更新或修訂任何前瞻性聲明的意圖或義務，也不解釋後續實際事件與這些前瞻性聲明之間的任何重大差異，除非適用法律要求。</p>
<p><em>交易所及其監管服務提供者（根據交易所政策定義的術語）對本公告的充分性或準確性不承擔責任。</em></p>
<p>來源：Devonian Health Group Inc.</p>

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

DNLI

AMPGW

動態生物技術與基因組 ETF - Invesco

<p>Devonian Health Group Inc. 已任命 Dennis Turpin 為首席財務官，立即生效。Turpin 是一位在生物製藥行業擁有超過 25 年經驗的資深高管，他還將繼續擔任董事會成員。他接替 Viktoria Krasteva，後者將在過渡期間協助，直到 2026 年 2 月。此外，Turpin 獲得了 25,000 個股票期權，行使價格為 11.50 美元。公司對之前的股票期權授予進行了修正，將行使價格從 0.18 美元調整為 0.19 美元，合併後的期權現在反映的價格為 11.40 美元</p>

<p>, /PRNewswire/ - Devonian Health Group Inc. (&#34; <strong>Devonian</strong>&#34; or the &#34; <strong>Company</strong>&#34;) (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, is pleased to announce that it has appointed Dennis Turpin as Chief Financial Officer of the Company, effective today. Mr. Turpin currently serves and will remain on the Board of Directors of the Company. Before his appointment as Chief Financial Officer, he also served as Chair of the Audit Committee, a role that will now be assumed by Mr. Pierre Labbé.</p>
<div class="lb-trans"><p>/PRNewswire/ - 德沃尼健康集團公司（&#34; <strong>Devonian</strong>&#34; 或 &#34; <strong>公司</strong>&#34;）（TSXV: GSD）（OTCQB: DVHGF）是一家專注於開發獨特解決方案以應對纖維炎症疾病的臨牀階段公司，欣然宣佈已任命丹尼斯·圖爾平（Dennis Turpin）為公司首席財務官，任命即日生效。圖爾平先生目前擔任公司董事會成員，並將繼續留任。在擔任首席財務官之前，他還曾擔任審計委員會主席，該職位將由皮埃爾·拉貝（Pierre Labbé）接任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg" alt="" original-src="https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg"/></p>
<p>Mr. Turpin is a seasoned professional executive and chartered professional accountant (CPA) with significant experience in finance, capital markets transactions, business development as well as mergers and acquisitions, over 25 years of which have been in the biopharmaceutical industry.</p>
<div class="lb-trans"><p>圖爾平先生是一位經驗豐富的職業高管和註冊專業會計師（CPA），在財務、資本市場交易、業務發展以及併購方面擁有超過 25 年的豐富經驗，其中大部分時間在生物製藥行業工作。</p>
</div><p><em>&#34;I am pleased to welcome Dennis and confident that he will help strengthen our management approach, diversify our perspectives, enhance our collective expertise, and help guide the development of Devonian.&#34; said Dr. André P. Boulet, PhD, Chief Executive Officer.</em></p>
<div class="lb-trans"><p><em>&#34;我很高興歡迎丹尼斯，並相信他將幫助加強我們的管理方法，豐富我們的視角，提升我們的集體專業知識，並指導德沃尼的發展。&#34;首席執行官安德烈·P·布萊特（André P. Boulet）博士表示。</em></p>
</div><p>Mr. Turpin will replace Viktoria Krasteva, who will remain with the Company and assist ensuring a smooth transition until February27, 2026. The Board would like to thank Ms. Krasteva for her contributions to the Company and wishes her well in her future endeavors.</p>
<div class="lb-trans"><p>圖爾平先生將接替維克托里亞·克拉斯特瓦（Viktoria Krasteva），後者將繼續留在公司，協助確保在 2026 年 2 月 27 日之前的順利過渡。董事會感謝克拉斯特瓦女士對公司的貢獻，並祝願她在未來的事業中一切順利。</p>
</div><p>A total of 25,000 stock options were granted to Mr. Turpin. These options are vesting immediately and are exercisable at a price of $11.50, for a period of 10 years following the grant date.</p>
<div class="lb-trans"><p>共向圖爾平先生授予 25,000 股股票期權。這些期權立即生效，行使價格為 11.50 美元，行使期限為授予日期後的 10 年。</p>
</div><p><strong>Options Grant Updates</strong></p>
<div class="lb-trans"><p><strong>期權授予更新</strong></p>
</div><p>The Company also wishes to correct the press release issued on December 19, 2025, regarding the granting of 2,948,056 stock options to directors and a consultant of the Company, as well as the additional grants of 385,950 stock options to employees and 100,000 stock options to a research and development consultant. Pursuant to the terms of the stock option plan, the exercise price of stock options may not be set below the market price of the common shares at the close of trading on the exchange on the trading day immediately preceding the grant date. Accordingly, the exercise price previously disclosed as $0.18 has been corrected to $0.19, being the applicable market price at the close of trading on the exchange on the trading day immediately preceding the grant date. All other terms of the stock option grants remain unchanged. Further to the share consolidation completed by the Company on January 22, 2026, on the basis of one post‑consolidation common share for every 60 pre‑consolidation common shares, the stock options described above have been automatically adjusted in accordance with the terms of the Company's stock option plan. As a result, each block of 60 pre‑consolidation options now represents one post‑consolidation option, and the corrected exercise price of $0.19 per share has been adjusted to $11.40 per share on a post‑consolidation basis. The number of options has been rounded down to the next lowest whole in order to allow the holder to purchase only a whole number of common shares upon exercise.</p>
<div class="lb-trans"><p>公司還希望更正於 2025 年 12 月 19 日發佈的新聞稿，關於向公司董事和顧問授予 2,948,056 股股票期權，以及向員工授予 385,950 股股票期權和向一名研發顧問授予 100,000 股股票期權。根據股票期權計劃的條款，股票期權的行使價格不得低於授予日期前一個交易日收盤時普通股的市場價格。因此，之前披露的行使價格 0.18 美元已更正為 0.19 美元，這是授予日期前一個交易日收盤時的適用市場價格。所有其他股票期權授予的條款保持不變。根據公司於 2026 年 1 月 22 日完成的股份合併，每 60 股合併前普通股對應 1 股合併後普通股，上述股票期權已根據公司股票期權計劃的條款自動調整。因此，每 60 股合併前期權現在代表 1 股合併後期權，修正後的行使價格 0.19 美元已調整為合併後每股 11.40 美元。期權數量已向下取整至下一個最小整數，以便持有人在行使時僅能購買整股普通股。</p>
</div><p><strong>About Devonian</strong></p>
<div class="lb-trans"><p><strong>關於德沃尼</strong></p>
</div><p>Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.</p>
<div class="lb-trans"><p>德沃尼健康集團公司是一家臨牀階段製藥公司，專注於開發針對各種自身免疫性纖維炎症疾病的藥物，採用新穎的治療方法以滿足未滿足的醫療需求。德沃尼的核心戰略是開發用於治療纖維炎症自身免疫疾病的處方藥，包括但不限於特應性皮炎、放射性皮炎和潰瘍性結腸炎。</p>
</div><p>Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.</p>
<div class="lb-trans"><p>德沃尼還參與開發高價值的藥妝產品，利用與其製藥產品相同的專有方法。德沃尼還擁有一家商業化子公司 Altius Healthcare LP，專注於在加拿大銷售處方藥，獲得品牌製藥公司的許可。</p>
</div><p>Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the &#34; <strong>Exchange</strong>&#34;) ( <strong>TSXV: GSD</strong>) and currently quoted on the OTCQB Venture Market ( <strong>OTCQB: DVHGF</strong>).</p>
<div class="lb-trans"><p>德沃尼健康集團公司成立於 2015 年，總部位於加拿大魁北克，擁有一座先進的提取設施。德沃尼在多倫多證券交易所創業板（&#34; <strong>交易所</strong>&#34;）（ <strong>TSXV: GSD</strong>）上市，並目前在 OTCQB 創業市場（ <strong>OTCQB: DVHGF</strong>）報價。</p>
</div><p>For more information, visit www.groupedevonian.com.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.groupedevonian.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong> All statements, other than statements of historical fact, contained in this press release including, the above &#34;About Devonian&#34; paragraph, all of which essentially describes the Company's outlook, constitute &#34;forward-looking information&#34; or &#34;forward-looking statements&#34; within the meaning of certain securities laws (collectively, &#34;forward-looking statements&#34;), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as &#34;intends&#34;, &#34;believes&#34;, &#34;expects&#34;, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results &#34;may&#34;, &#34;could&#34;, &#34;would&#34;, or &#34;will&#34; be taken, occur or be achieved.</p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong> 本新聞稿中包含的所有聲明，除了歷史事實聲明外，包括上述&#34;關於德沃尼&#34;段落，均構成某些證券法意義上的&#34;前瞻性信息&#34;或&#34;前瞻性聲明&#34;（統稱為&#34;前瞻性聲明&#34;），並基於本新聞稿發佈時的預期、估計和預測。這些前瞻性聲明可能通過使用諸如&#34;打算&#34;、&#34;相信&#34;、&#34;期望&#34;或這些詞和短語的變體（包括否定和語法變體）來識別，或表明某些行動、事件或結果&#34;可能&#34;、&#34;可以&#34;、&#34;將&#34;或&#34;會&#34;被採取、發生或實現。</p>
</div><p>Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.</p>
<div class="lb-trans"><p>前瞻性聲明必然基於許多估計和假設，儘管公司在作出這些聲明時認為這些估計和假設是合理的，但本質上仍然受到重大商業、經濟和競爭不確定性及偶發事件的影響。這些估計和假設可能被證明是錯誤的。許多不確定性和偶發事件可能直接或間接影響實際結果，並可能導致實際結果與任何前瞻性聲明中所表達或暗示的結果存在重大差異。不能保證這些假設會被證明是正確的，也不能保證前瞻性聲明會被證明是準確的，因為實際結果和未來事件可能與這些聲明中預期的結果存在重大差異。</p>
</div><p>By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.</p>
<div class="lb-trans"><p>由於其本質，前瞻性聲明涉及固有的風險和不確定性，包括一般性和特定性風險，存在估計、預測、展望和其他前瞻性聲明未能實現或假設未能反映未來經驗的風險。前瞻性聲明的目的是提供有關管理層對未來的期望和計劃的信息。讀者應謹慎對待這些前瞻性聲明，不應過度依賴，因為許多重要的風險因素和未來事件可能導致實際結果與這些前瞻性聲明中表達的信念、計劃、目標、期望、預期、估計、假設和意圖存在重大差異。本新聞稿中所作的所有前瞻性聲明均受到這些警示性聲明以及我們在加拿大相關證券監管機構的其他文件中所作聲明的限制。公司不承擔更新或修訂任何前瞻性聲明的意圖或義務，也不解釋後續實際事件與這些前瞻性聲明之間的任何重大差異，除非適用法律要求。</p>
</div><p><em>Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.</em></p>
<div class="lb-trans"><p><em>交易所及其監管服務提供者（根據交易所政策定義的術語）對本公告的充分性或準確性不承擔責任。</em></p>
</div><p>SOURCE Devonian Health Group Inc.</p>
<div class="lb-trans"><p>來源：Devonian Health Group Inc.</p>
</div>

DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT | DVHGF Stock News

StockTitan

Denali Therap

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)

泥盆紀公司任命 Dennis Turpin 為首席財務官，並提供有關股票期權授予的最新信息 | DVHGF 股票新聞